Department of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany.
Department of Pneumology, Hannover Medical School, Hannover, Germany.
Perfusion. 2023 Oct;38(7):1393-1398. doi: 10.1177/02676591221113135. Epub 2022 Jul 4.
Severe acute respiratory distress syndrome (ARDS) due to Coronavirus Disease-19 (COVID-19) is associated with high mortality. Although survival on mechanical circulatory support has improved, determinants for better prognosis are still unclear. Here, we report on the outcome of our patient population with the need for mechanical circulatory support due to severe COVID-19 (sCOVID-19) induced ARDS.
All patients treated with extracorporeal membrane oxygenation (ECMO) for severe ARDS due to sCOVID-19 were analysed. Patients > 18 years of age at the time of initiation of ECMO were included. Pre-existing comorbidities, complications during ECMO implantation, and ECMO runtime were reviewed. The latency to intubation, proning, tracheotomy, and ECMO implantation was analysed. Furthermore, the survival and non-survival population were compared to determine factors in favour of a better outcome.
In total, 85 patients were treated with veno-venous membrane oxygenation (vv-ECMO) for severe ARDS in our medical centre. The patient population was predominantly male (83.5%) with a mean patient age of 54.9 years. A history of cardiovascular disease ( = .01), smoking ( < .05), need for vasopressor- ( < .05), and renal replacement therapy ( < .001) was associated with a worse prognosis. Overall survival was 50%. The survival population was significantly younger ( = .004), had a significantly higher body weight ( = .02) and body mass index (BMI) ( = .01). Furthermore, survival was significantly better when vv-ECMO was initiated within 48 h after admission ( < .001).
Pre-existing cardiovascular disease, higher age, history of nicotine abuse, and development of renal failure are associated with poor outcome. Early start of vv-ECMO therapy may lead to better survival in sCOVID-19 patients, although complications during ECMO therapy are associated with a worse prognosis.
由新型冠状病毒病(COVID-19)引起的严重急性呼吸窘迫综合征(ARDS)与高死亡率相关。尽管使用机械循环支持的存活率有所提高,但预后较好的决定因素仍不清楚。在这里,我们报告了因严重 COVID-19(sCOVID-19)引起的 ARDS 而需要机械循环支持的患者人群的结果。
分析了所有因 sCOVID-19 导致严重 ARDS 并接受体外膜氧合(ECMO)治疗的患者。纳入年龄在 ECMO 开始时大于 18 岁的患者。回顾了 ECMO 植入前的合并症、并发症和 ECMO 运行时间。分析了插管、俯卧位、气管切开术和 ECMO 植入的潜伏期。此外,比较了存活和非存活人群,以确定有利于更好结局的因素。
在我们的医疗中心,共有 85 例患者因严重 ARDS 接受了静脉-静脉膜氧合(vv-ECMO)治疗。患者人群主要为男性(83.5%),平均年龄为 54.9 岁。心血管疾病史( <.01)、吸烟史( <.05)、需要血管加压素( <.05)和肾脏替代治疗( <.001)与预后不良相关。总体生存率为 50%。存活组明显更年轻( <.004),体重明显更高( <.02),体重指数(BMI)明显更高( <.01)。此外,入院后 48 小时内开始 vv-ECMO 治疗的生存率明显更高( <.001)。
预先存在的心血管疾病、年龄较大、尼古丁滥用史和肾衰竭的发展与不良预后相关。早期开始 vv-ECMO 治疗可能会导致 sCOVID-19 患者的生存率提高,尽管 ECMO 治疗期间的并发症与预后较差相关。